TMDX Stock: Can Transmedics Maintain 30%+ Growth in 2026?

Transmedics (TMDX) finished a great fiscal year in2025, but the market is reacting to some interesting shifts in their 2026 guidance. In this video, we break down why this organ care leader is a small bet in the Chip Stock Investor portfolio and what the inflection point from operating loss to profit means for long-term holders. In this video, we cover:--37% annual revenue growth and the Q4 beat.-- How sensors and semiconductor connectivity are replacing the ice chest legacy of organ transport.--Why Transmedics bought an aviation company and how their fleet of 22 aircraft is changing the game.--2026 Headwinds: We discuss the expected margin compression, international expansion costs in Italy and Europe, and the "seasonal" Q3 dip that always surprises the market.--Future Catalysts: The Kidney program, OCS Generation 3, and functional enhancement of donor hearts. Join us on Discord with Semiconductor Insider, sign up on our website: www.chipstockinvestor.com/membership Supercharge your analysis with AI! Get 15% of your membership with our special link here: https://fiscal.ai/csi/ Sign Up For Our Newsletter: https://mailchi.mp/b1228c12f284/sign-up-landing-page-short-form If you found this video useful, please make sure to like and subscribe! Chapters:00:00 —Transmedics 2025 Wrap-up 01:15 — The Q3 Seasonality Mystery Explained 02:30 — Q4 Financial Breakdown: Revenue & Margins 03:45 — Disrupting the Market: Transmedics vs. Cold Storage 05:10 — Scaling the Fleet: Logistics & Owned Aircraft 06:30 — Revenue by Organ: Liver, Heart, and Lung 07:45 — The "Chip" Connection: Sensors and Data 09:15 — Operating Profit Inflection Point 10:30 — 2026 Growth Opportunities: Kidney Program & Europe 12:00 — Headwinds: Competitive Trials & Infrastructure Costs 13:30 — 2026 Guidance: Revenue Deceleration & Margin Compression *********************************************************

Affiliate links that are sprinkled in throughout this video. If something catches your eye and you decide to buy it, we might earn a little coffee money. Thanks for helping us (Kasey) fuel our caffeine addiction! Content in this video is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. #Transmedics #TMDX #ChipStockInvestor #MedTech #GrowthStocks #Investing #StockMarket2026 #organtransplantation Nick and Kasey own shares of TMDX

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(462)

Solstice's $4.5B Element Solutions Deal: Why It Sold Off

Solstice Advanced Materials is acquiring Element Solutions (NYSE: ESI) in a $4.5 billion deal that would create a combined semiconductor and electronics materials supplier generating close to $8 billi...

17 Heinä 12min

Hyperscaler CapEx Hits $800B: Why Memory & Optical Stocks Are Booming

Hyperscaler capital expenditure is on pace to hit $800 billion in 2026, up from $482 billion just a few quarters ago, and the trajectory points toward $1 trillion by 2027. This is the real driver behi...

16 Heinä 5min

Qualcomm Is Quietly Becoming an AI Data Center Stock

Qualcomm just held its 2026 Investor Day, and the headline number is a new $15 billion AI data center revenue target for 2029 — up from essentially zero two years ago. We break down whether this fable...

14 Heinä 11min

IBM NanoStack CFET: Turning Patents Into Chip Royalties

IBM just unveiled NanoStack, its take on the CFET transistor architecture that succeeds gate-all-around as the next step in chip scaling — and it could turn IBM's patent portfolio into a real semicond...

10 Heinä 15min

Jensen Called Marvell a $1T Stock — We're Not Buying It

Marvell (NASDAQ: MRVL) stock has surged since Jensen Huang called it the next trillion-dollar company — we ran a reverse DCF on the Q1 FY2027 earnings to see if the rally is justified.Marvell just pos...

7 Heinä 11min

Memory & Optical Stocks Up 100%+ in 2026: Why We're Not Selling (Micron, SK Hynix, SanDisk, Lumentum)

Memory and optical semiconductor stocks have been the standout trade of 2026, with holdings like Micron, SK Hynix, and SanDisk up well over 100% year-to-date on tight supply and rising pricing. In thi...

4 Heinä 11min

Cybersecurity & Capital Allocation: Is Rubrik (RBRK) a Buy?

Rubrik (RBRK) stock is down near $70 after peaking above $89 — but its subscription ARR is still growing over 30%. Here's the reverse DCF and margin math behind why the recovery has stalled.Rubrik (NY...

2 Heinä 10min

Micron's $100 Billion Backlog: Are Take-or-Pay Agreements Changing the Memory Cycle?

The memory chip industry has historically been plagued by vicious boom-and-bust cycles, but Micron is taking aggressive steps to rewrite the rules. In this episode of Chip Stock Investor, we discuss S...

30 Kesä 17min